Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3)

被引：0
|
作者：
Seyoung Seo
Min-Hee Ryu
Young Soo Park
Ji Yong Ahn
Yangsoon Park
Sook Ryun Park
Baek-Yeol Ryoo
Gin Hyug Lee
Hwoon-Young Jung
Yoon-Koo Kang
机构：
[1] University of Ulsan College of Medicine,Department of Oncology, Asan Medical Center
[2] University of Ulsan College of Medicine,Department of Pathology, Asan Medical Center
[3] University of Ulsan College of Medicine,Department of Gastroenterology, Asan Medical Center
来源：
Gastric Cancer | 2019年 / 22卷
关键词：
HER2; Advanced gastric cancer; Heterogeneity; Trastuzumab; T-DM1;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：527 / 535
页数：8
相关论文
共 50 条
  • [1] Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3)
    Seo, Seyoung
    Ryu, Min-Hee
    Park, Young Soo
    Ahn, Ji Yong
    Park, Yangsoon
    Park, Sook Ryun
    Ryoo, Baek-Yeol
    Lee, Gin Hyug
    Jung, Hwoon-Young
    Kang, Yoon-Koo
    [J]. GASTRIC CANCER, 2019, 22 (03) : 527 - 535
  • [2] Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: Results of GASTric cancer HER2 reassessment study 3 (GASTHER3).
    Seo, Seyoung
    Ryu, Min-Hee
    Ahn, Ji Yong
    Park, Yangsoon
    Park, Sook Ryun
    Ryoo, Baek-Yeol
    Park, Young Soo
    Lee, Gin Hyug
    Jung, Hwoon-Yong
    Kang, Yoon-Koo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [3] Loss of HER2 Positivity after Trastuzumab in HER2-Positive Gastric Cancer: Is Change in HER2 Status Significantly Frequent?
    Ishimine, Yu
    Goto, Akira
    Watanabe, Yoshito
    Yajima, Hidetaka
    Nakagaki, Suguru
    Yabana, Takashi
    Adachi, Takeya
    Kondo, Yoshihiro
    Kasai, Kiyoshi
    [J]. CASE REPORTS IN GASTROINTESTINAL MEDICINE, 2015, 2015
  • [4] HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer
    Akio Kaito
    Takeshi Kuwata
    Masanori Tokunaga
    Kohei Shitara
    Reo Sato
    Tetsuo Akimoto
    Takahiro Kinoshita
    [J]. World Journal of Clinical Cases, 2019, (15) : 1964 - 1977
  • [5] HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer
    Kaito, Akio
    Kuwata, Takeshi
    Tokunaga, Masanori
    Shitara, Kohei
    Sato, Reo
    Akimoto, Tetsuo
    Kinoshita, Takahiro
    [J]. WORLD JOURNAL OF CLINICAL CASES, 2019, 7 (15) : 1964 - 1977
  • [6] Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER2 reassessment study 1 (GASTHER1)
    Park, Sook Ryun
    Park, Young Soo
    Ryu, Min-Hee
    Ryoo, Baek-Yeol
    Woo, Chang Gok
    Jung, Hwoon-Yong
    Lee, Jeong Hoon
    Lee, Gin Hyug
    Kang, Yoon-Koo
    [J]. EUROPEAN JOURNAL OF CANCER, 2016, 53 : 42 - 50
  • [7] Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients
    Guarneri, V.
    Dieci, M. V.
    Barbieri, E.
    Piacentini, F.
    Omarini, C.
    Ficarra, G.
    Bettelli, S.
    Conte, P. F.
    [J]. ANNALS OF ONCOLOGY, 2013, 24 (12) : 2990 - 2994
  • [8] HER2 positive breast cancer patients having HER2 loss after neoadjuvant chemotherapy should still be treated with adjuvant anti-HER2 treatment
    Kadri Altundag
    [J]. Breast Cancer Research and Treatment, 2019, 175 : 261 - 261
  • [9] HER2 positive breast cancer patients having HER2 loss after neoadjuvant chemotherapy should still be treated with adjuvant anti-HER2 treatment
    Altundag, Kadri
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2019, 175 (01) : 261 - 261
  • [10] HER2-positive gastric cancer identified by serum HER2: A case report
    Saito, Mayuko
    Kawakami, Yujiro
    Yamashita, Kentaro
    Nasuno, Hiroshi
    Ishimine, Yu
    Fukuda, Koichiro
    Isshiki, Hiroyuki
    Suzuki, Ryo
    Arimura, Yoshiaki
    Shinomura, Yasuhisa
    [J]. ONCOLOGY LETTERS, 2016, 11 (06) : 3575 - 3578
12345